Human β-defensin 2 plays a regulatory role in innate antiviral immunity and is capable of potentiating the induction of antigen-specific immunity.
Identifieur interne : 000820 ( PubMed/Corpus ); précédent : 000819; suivant : 000821Human β-defensin 2 plays a regulatory role in innate antiviral immunity and is capable of potentiating the induction of antigen-specific immunity.
Auteurs : Ju Kim ; Ye Lin Yang ; Sun-Hee Jang ; Yong-Suk JangSource :
- Virology journal [ 1743-422X ] ; 2018.
English descriptors
- KwdEn :
- Adaptive Immunity (immunology), Adjuvants, Immunologic (administration & dosage), Animals, Antibodies, Neutralizing (blood), Antibodies, Viral (blood), Antigens, Viral (chemistry), Antigens, Viral (immunology), Antiviral Agents (immunology), Cell Line, Tumor, Chlorocebus aethiops, Coronavirus Infections (immunology), Coronavirus Infections (prevention & control), Female, Humans, Immunity, Innate (immunology), Macrophages (immunology), Mice, Mice, Inbred C57BL, Middle East Respiratory Syndrome Coronavirus (chemistry), Middle East Respiratory Syndrome Coronavirus (immunology), Spike Glycoprotein, Coronavirus (chemistry), Spike Glycoprotein, Coronavirus (immunology), THP-1 Cells, Vaccines, Subunit (administration & dosage), Vaccines, Subunit (immunology), Vero Cells, Viral Vaccines (administration & dosage), Viral Vaccines (immunology), beta-Defensins (chemistry), beta-Defensins (immunology).
- MESH :
- chemical , administration & dosage : Adjuvants, Immunologic, Vaccines, Subunit, Viral Vaccines.
- chemical , blood : Antibodies, Neutralizing, Antibodies, Viral.
- chemical , chemistry : Antigens, Viral, Spike Glycoprotein, Coronavirus, beta-Defensins.
- chemistry : Middle East Respiratory Syndrome Coronavirus.
- immunology : Adaptive Immunity, Antigens, Viral, Antiviral Agents, Coronavirus Infections, Immunity, Innate, Macrophages, Middle East Respiratory Syndrome Coronavirus, Spike Glycoprotein, Coronavirus, Vaccines, Subunit, Viral Vaccines, beta-Defensins.
- prevention & control : Coronavirus Infections.
- Animals, Cell Line, Tumor, Chlorocebus aethiops, Female, Humans, Mice, Mice, Inbred C57BL, THP-1 Cells, Vero Cells.
Abstract
Antimicrobial peptides (AMPs) are primarily known for their innate immune defense against invading microorganisms, including viruses. In addition, recent research has suggested their modulatory activity in immune induction. Given that most subunit vaccines require an adjuvant to achieve effective immune induction through the activation of innate immunity, AMPs are plausible candidate molecules for stimulating not only innate immune but also adaptive immune responses.
DOI: 10.1186/s12985-018-1035-2
PubMed: 30089512
Links to Exploration step
pubmed:30089512Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Human β-defensin 2 plays a regulatory role in innate antiviral immunity and is capable of potentiating the induction of antigen-specific immunity.</title>
<author><name sortKey="Kim, Ju" sort="Kim, Ju" uniqKey="Kim J" first="Ju" last="Kim">Ju Kim</name>
<affiliation><nlm:affiliation>Department of Molecular Biology and the Institute for Molecular Biology and Genetics, Chonbuk National University, Jeonju, 54896, Korea.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Yang, Ye Lin" sort="Yang, Ye Lin" uniqKey="Yang Y" first="Ye Lin" last="Yang">Ye Lin Yang</name>
<affiliation><nlm:affiliation>Department of Bioactive Material Sciences and Institute of Bioactive Materials, Chonbuk National University, Jeonju, 54896, Korea.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Jang, Sun Hee" sort="Jang, Sun Hee" uniqKey="Jang S" first="Sun-Hee" last="Jang">Sun-Hee Jang</name>
<affiliation><nlm:affiliation>Department of Molecular Biology and the Institute for Molecular Biology and Genetics, Chonbuk National University, Jeonju, 54896, Korea.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Jang, Yong Suk" sort="Jang, Yong Suk" uniqKey="Jang Y" first="Yong-Suk" last="Jang">Yong-Suk Jang</name>
<affiliation><nlm:affiliation>Department of Molecular Biology and the Institute for Molecular Biology and Genetics, Chonbuk National University, Jeonju, 54896, Korea. yongsuk@jbnu.ac.kr.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2018">2018</date>
<idno type="RBID">pubmed:30089512</idno>
<idno type="pmid">30089512</idno>
<idno type="doi">10.1186/s12985-018-1035-2</idno>
<idno type="wicri:Area/PubMed/Corpus">000820</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000820</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Human β-defensin 2 plays a regulatory role in innate antiviral immunity and is capable of potentiating the induction of antigen-specific immunity.</title>
<author><name sortKey="Kim, Ju" sort="Kim, Ju" uniqKey="Kim J" first="Ju" last="Kim">Ju Kim</name>
<affiliation><nlm:affiliation>Department of Molecular Biology and the Institute for Molecular Biology and Genetics, Chonbuk National University, Jeonju, 54896, Korea.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Yang, Ye Lin" sort="Yang, Ye Lin" uniqKey="Yang Y" first="Ye Lin" last="Yang">Ye Lin Yang</name>
<affiliation><nlm:affiliation>Department of Bioactive Material Sciences and Institute of Bioactive Materials, Chonbuk National University, Jeonju, 54896, Korea.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Jang, Sun Hee" sort="Jang, Sun Hee" uniqKey="Jang S" first="Sun-Hee" last="Jang">Sun-Hee Jang</name>
<affiliation><nlm:affiliation>Department of Molecular Biology and the Institute for Molecular Biology and Genetics, Chonbuk National University, Jeonju, 54896, Korea.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Jang, Yong Suk" sort="Jang, Yong Suk" uniqKey="Jang Y" first="Yong-Suk" last="Jang">Yong-Suk Jang</name>
<affiliation><nlm:affiliation>Department of Molecular Biology and the Institute for Molecular Biology and Genetics, Chonbuk National University, Jeonju, 54896, Korea. yongsuk@jbnu.ac.kr.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Virology journal</title>
<idno type="eISSN">1743-422X</idno>
<imprint><date when="2018" type="published">2018</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adaptive Immunity (immunology)</term>
<term>Adjuvants, Immunologic (administration & dosage)</term>
<term>Animals</term>
<term>Antibodies, Neutralizing (blood)</term>
<term>Antibodies, Viral (blood)</term>
<term>Antigens, Viral (chemistry)</term>
<term>Antigens, Viral (immunology)</term>
<term>Antiviral Agents (immunology)</term>
<term>Cell Line, Tumor</term>
<term>Chlorocebus aethiops</term>
<term>Coronavirus Infections (immunology)</term>
<term>Coronavirus Infections (prevention & control)</term>
<term>Female</term>
<term>Humans</term>
<term>Immunity, Innate (immunology)</term>
<term>Macrophages (immunology)</term>
<term>Mice</term>
<term>Mice, Inbred C57BL</term>
<term>Middle East Respiratory Syndrome Coronavirus (chemistry)</term>
<term>Middle East Respiratory Syndrome Coronavirus (immunology)</term>
<term>Spike Glycoprotein, Coronavirus (chemistry)</term>
<term>Spike Glycoprotein, Coronavirus (immunology)</term>
<term>THP-1 Cells</term>
<term>Vaccines, Subunit (administration & dosage)</term>
<term>Vaccines, Subunit (immunology)</term>
<term>Vero Cells</term>
<term>Viral Vaccines (administration & dosage)</term>
<term>Viral Vaccines (immunology)</term>
<term>beta-Defensins (chemistry)</term>
<term>beta-Defensins (immunology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term>
<term>Vaccines, Subunit</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Neutralizing</term>
<term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antigens, Viral</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>beta-Defensins</term>
</keywords>
<keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Adaptive Immunity</term>
<term>Antigens, Viral</term>
<term>Antiviral Agents</term>
<term>Coronavirus Infections</term>
<term>Immunity, Innate</term>
<term>Macrophages</term>
<term>Middle East Respiratory Syndrome Coronavirus</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Vaccines, Subunit</term>
<term>Viral Vaccines</term>
<term>beta-Defensins</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cell Line, Tumor</term>
<term>Chlorocebus aethiops</term>
<term>Female</term>
<term>Humans</term>
<term>Mice</term>
<term>Mice, Inbred C57BL</term>
<term>THP-1 Cells</term>
<term>Vero Cells</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Antimicrobial peptides (AMPs) are primarily known for their innate immune defense against invading microorganisms, including viruses. In addition, recent research has suggested their modulatory activity in immune induction. Given that most subunit vaccines require an adjuvant to achieve effective immune induction through the activation of innate immunity, AMPs are plausible candidate molecules for stimulating not only innate immune but also adaptive immune responses.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30089512</PMID>
<DateCompleted><Year>2018</Year>
<Month>12</Month>
<Day>27</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>12</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-422X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>15</Volume>
<Issue>1</Issue>
<PubDate><Year>2018</Year>
<Month>08</Month>
<Day>08</Day>
</PubDate>
</JournalIssue>
<Title>Virology journal</Title>
<ISOAbbreviation>Virol. J.</ISOAbbreviation>
</Journal>
<ArticleTitle>Human β-defensin 2 plays a regulatory role in innate antiviral immunity and is capable of potentiating the induction of antigen-specific immunity.</ArticleTitle>
<Pagination><MedlinePgn>124</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/s12985-018-1035-2</ELocationID>
<Abstract><AbstractText Label="BACKGROUND">Antimicrobial peptides (AMPs) are primarily known for their innate immune defense against invading microorganisms, including viruses. In addition, recent research has suggested their modulatory activity in immune induction. Given that most subunit vaccines require an adjuvant to achieve effective immune induction through the activation of innate immunity, AMPs are plausible candidate molecules for stimulating not only innate immune but also adaptive immune responses.</AbstractText>
<AbstractText Label="RESULTS">In this study, we investigated the ability of human β-defensin (HBD) 2 to promote antiviral immunity in vitro and in vivo using a receptor-binding domain (RBD) of Middle East respiratory syndrome-coronavirus (MERS-CoV) spike protein (S RBD) as a model antigen (Ag). When HBD 2-conjugated S RBD was used to treat THP-1 human monocytic cells, the expression levels of antiviral (IFN-β, IFN-γ, MxA, PKR, and RNaseL) and primary immune-inducing (NOD2, TNF-α, IL-1β, and IL-6) molecules were enhanced compared to those expressed after treatment with S RBD only. The expression of chemokines capable of recruiting leukocytes, including monocytes/macrophages, natural killer cells, granulocytes, T cells, and dendritic cells, was also increased following HBD 2-conjugated S RBD treatment. More important, immunization of mice with HBD 2-conjugated S RBD enhanced the immunogenicity of the S RBD and elicited a higher S RBD-specific neutralizing antibody response than S RBD alone.</AbstractText>
<AbstractText Label="CONCLUSIONS">We conclude that HBD 2 activates the primary antiviral innate immune response and may also mediate the induction of an effective adaptive immune response against a conjugated Ag.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName>
<ForeName>Ju</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Department of Molecular Biology and the Institute for Molecular Biology and Genetics, Chonbuk National University, Jeonju, 54896, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Yang</LastName>
<ForeName>Ye Lin</ForeName>
<Initials>YL</Initials>
<AffiliationInfo><Affiliation>Department of Bioactive Material Sciences and Institute of Bioactive Materials, Chonbuk National University, Jeonju, 54896, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jang</LastName>
<ForeName>Sun-Hee</ForeName>
<Initials>SH</Initials>
<AffiliationInfo><Affiliation>Department of Molecular Biology and the Institute for Molecular Biology and Genetics, Chonbuk National University, Jeonju, 54896, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jang</LastName>
<ForeName>Yong-Suk</ForeName>
<Initials>YS</Initials>
<Identifier Source="ORCID">0000-0002-1675-4224</Identifier>
<AffiliationInfo><Affiliation>Department of Molecular Biology and the Institute for Molecular Biology and Genetics, Chonbuk National University, Jeonju, 54896, Korea. yongsuk@jbnu.ac.kr.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Bioactive Material Sciences and Institute of Bioactive Materials, Chonbuk National University, Jeonju, 54896, Korea. yongsuk@jbnu.ac.kr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>CRC-16-01-KRICT</GrantID>
<Agency>Korea National Research Counsil of Science & Technology</Agency>
<Country>International</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2018</Year>
<Month>08</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Virol J</MedlineTA>
<NlmUniqueID>101231645</NlmUniqueID>
<ISSNLinking>1743-422X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C106641">DEFB4A protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D022223">Vaccines, Subunit</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D023083">beta-Defensins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D056704" MajorTopicYN="N">Adaptive Immunity</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000074084" MajorTopicYN="N">THP-1 Cells</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D022223" MajorTopicYN="N">Vaccines, Subunit</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D023083" MajorTopicYN="N">beta-Defensins</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Adjuvant</Keyword>
<Keyword MajorTopicYN="Y">Antibody</Keyword>
<Keyword MajorTopicYN="Y">Antigen</Keyword>
<Keyword MajorTopicYN="Y">Human β-defensin</Keyword>
<Keyword MajorTopicYN="Y">MERS-CoV</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year>
<Month>01</Month>
<Day>12</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2018</Year>
<Month>07</Month>
<Day>30</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2018</Year>
<Month>8</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2018</Year>
<Month>8</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2018</Year>
<Month>12</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">30089512</ArticleId>
<ArticleId IdType="doi">10.1186/s12985-018-1035-2</ArticleId>
<ArticleId IdType="pii">10.1186/s12985-018-1035-2</ArticleId>
<ArticleId IdType="pmc">PMC6083524</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Vaccine. 2014 Oct 21;32(46):6170-6176</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25240756</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2005 Feb 4;307(5710):731-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15692051</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2002 Nov 1;277(44):41701-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12194982</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Immunol. 2005 Aug;17(4):359-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15955682</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viral Immunol. 2017 Jul/Aug;30(6):463-470</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28436755</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2002 Nov 1;298(5595):1025-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12411706</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rev Sci Tech. 1998 Apr;17(1):220-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9638812</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunol Rev. 2012 Jan;245(1):84-112</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22168415</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int Immunol. 2000 May;12(5):691-700</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10784615</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2001 Feb 16;276(7):4812-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11087742</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 2014 Jan;52(1):67-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24153118</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 1996 Feb 9;271(6):2935-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8621683</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2009 Jun;83(11):5451-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19297479</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immune Netw. 2017 Oct;17(5):326-342</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29093654</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2010 Jun 15;184(12):6688-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20483750</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Immun. 2018 Feb 20;86(3):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29263112</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gut. 2003 Nov;52(11):1591-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14570728</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2009 May;83(9):4489-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19211762</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2004 Nov 25;351(22):2286-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15525713</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Immunol. 2003 Jan;4(1):69-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12483210</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2001 Dec 1;167(11):6644-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11714836</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immune Netw. 2015 Apr;15(2):51-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25922593</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2000 Oct;81(Pt 10):2341-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10993923</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 1994 Jun 24;264(5167):1918-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8009221</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 1999 Oct 15;286(5439):525-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10521347</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2015 Apr;89(7):3659-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25589660</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Intervirology. 2016;59(1):8-19</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27318958</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Biol. 2013 Dec 13;425(24):4965-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24095897</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Immunol. 2009 Oct;10(10):1073-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19701189</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Pharm Des. 2009;15(21):2377-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19601838</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2010 Jan 13;5(1):e8668</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20084270</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2003 Nov;62 Suppl 2:ii17-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14532141</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2013 Dec 04;8(12):e81587</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24324708</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2016 Jun 30;34(31):3620-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27228947</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int Rev Immunol. 2013 Apr;32(2):209-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23570316</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Leukoc Biol. 2008 Apr;83(4):998-1008</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18192488</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2007 Feb;81(3):1162-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17108019</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000820 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000820 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= MersV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:30089512 |texte= Human β-defensin 2 plays a regulatory role in innate antiviral immunity and is capable of potentiating the induction of antigen-specific immunity. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:30089512" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a MersV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |